Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexo, a developer of treatments for pain and inflammation, has concluded its first clinical trial of OX27, a sublingual tablet developed for optimizing the treatment of breakthrough pain in cancer patients.
Subscribe to our email newsletter
Orexo is planning to start and conclude the next clinical study in healthy volunteers in the fourth quarter of 2011.
Orexo president and CEO Anders Lundstrom said OX27 has the potential to improve treatment of breakthrough pain in cancer patients.
"The successful outcome of this trial shows important progress for Orexo in building its proprietary pipeline, thus bringing us closer our defined goal of becoming a successful specialty pharma company," Lundstrom said.